Treatment
S-1 clinical trials
We’re tracking 792 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT04098315Recruiting
HIV drug-resistance patient registry study for people 14+
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
Milan, MIAges 14 years+ - NCT07143318RecruitingPhase 1
First-in-Human study of KLA578-1 for injection in healthy volunteers
This trial tests a new investigational drug for the first time in people. It will study how the drug is processed by the body in healthy volunteers. If you are a generally healthy adult, you may be able to help with this important early research.
Changsha, HunanAges 18–45 - NCT07131202RecruitingPhase 1/Phase 2
FL115 plus PD-1 antibody for advanced solid tumors
This trial tests a new drug called FL115 combined with an immunotherapy (PD-1 antibody) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–80 - NCT07125547RecruitingPhase 2
Immunotherapy and chemo before surgery for ureteral cancer
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (nab-paclitaxel) given before surgery for ureteral cancer. The goal is to see if the treatment shrinks the tumor and makes the surgery more effective.
Tianjin, Outside U.S.Ages 18 years+ - NCT07110103RecruitingPhase 2
Golidocitinib with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
BeijingAges 18 years+ - NCT07092605Enrolling by invitationEarly Phase 1
Microdosed semaglutide for longer, healthier life
This trial tests whether a very low ('micro') dose of semaglutide can improve health, quality of life, and how long you live well. It's for people who are interested in the drug's general health benefits but not specifically for weight loss.
Ann Arbor, MichiganAges 18–65 - NCT07092618RecruitingPhase 2/Phase 3
Trial for keeping weight off after stopping GLP-1 meds
This study tests if other medicines (naltrexone, metformin, or rapamycin) can help people keep off weight they lost while taking GLP-1 drugs like Wegovy or Ozempic, after they stop taking them. It is for AgelessRx patients aged 40 to 85 who have lost at least 15 pounds on GLP-1s.
Chicago, IllinoisAges 40–85 - NCT07086300Recruiting
Acupuncture with immunotherapy for older lung cancer patients
This trial tests whether adding electroacupuncture (a gentle, needle-based therapy) to a standard immunotherapy drug (PD-1 inhibitor) can help older adults with advanced lung cancer. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 65–100 - NCT06251115Recruiting
Study of QY-1-T for advanced HBV-related liver cancer
This study tests a new treatment called QY-1-T for people with advanced liver cancer related to hepatitis B. It is for patients who have already tried other standard treatments and have a certain genetic marker (HLA-A*11:01).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07068763RecruitingPhase 2
Short radiation plus drugs for early rectal cancer
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
Hangzhou, ZhejiangAges 18–80 - NCT06327178Recruiting
Sbrt and Immunotherapy for Advanced Kidney Cancer
This trial studies whether combining a special type of radiation (SBRT) with an immunotherapy (PD-1 blocker) can shrink kidney cancer that has already spread. It is for people who have already had this combination treatment before.
Guangzhou, GuangdongAges 18 years+ - NCT07050641RecruitingPhase 1/Phase 2
Study of SCTB39-1 for advanced solid tumors
This trial tests a new drug called SCTB39-1 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: first finding the right dose, then testing how well it works.
BeijingAges 18 years+ - NCT07050940Recruiting
Adding a gut supplement to immunotherapy for advanced melanoma
This trial tests whether adding a postbiotic (a gut-health supplement) to a standard immunotherapy called anti-PD-1 makes it work better for people with advanced melanoma that hasn't been treated yet. It may help shrink tumors or slow the cancer's growth.
Bari, BAAges 18 years+ - NCT06988592Recruiting
Chemo plus immunotherapy for advanced bile duct cancer
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07012642RecruitingEarly Phase 1
GLP-1 drugs for arm or leg swelling (lymphedema)
This trial tests if a class of diabetes drugs (GLP-1 receptor agonists) can reduce swelling in one arm or leg caused by lymphedema. It may help people who have not found relief from other treatments.
Red Bank, New JerseyAges 18 years+ - NCT07007182RecruitingPhase 2
Treating stomach cancer spread to lymph nodes with chemo, surgery, and radiation
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
Jinan, ShandongAges 18–75 - NCT07005570RecruitingPhase 2
Short radiation and chemo with or without immunotherapy for rectal cancer
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
Guangzhou, GuangdongAges 18–75 - NCT07001592RecruitingPhase 1
Injection of a modified virus for advanced GI and peritoneal cancers
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 18–69 - NCT06986785RecruitingPhase 2
Study of new drug combinations for advanced liver cancer
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06976619RecruitingPhase 2
Blood sugar control and a diabetes drug on insulin production
This study looks at how blood sugar control and a class of drugs called GLP-1 agonists (like Ozempic) affect insulin-making cells in people with type 1 or type 2 diabetes who use insulin.
Rochester, MinnesotaAges 25–70 - NCT06964568RecruitingPhase 3
Chemoradiation followed by immunotherapy for esophageal cancer
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
ShanghaiAges 18 years+ - NCT06958432RecruitingPhase 2/Phase 3
Shorter radiation before chemo and immunotherapy for rectal cancer
This trial tests a shorter course of radiation before chemotherapy and an immunotherapy drug to shrink mid-to-lower rectal cancer that has not spread. The goal is to improve treatment response and reduce side effects, potentially allowing for less invasive surgery.
Guangzhou, GuangdongAges 18–75 - NCT06928922RecruitingEarly Phase 1
Inhaled mRNA vaccine for advanced lung cancer and lung metastases
This trial tests an inhaled dry powder vaccine that uses mRNA to help your immune system target cancer cells in the lungs. It is for people with advanced lung cancer or solid tumors that have spread to the lungs, who have already tried standard treatments.
BeijingAges Up to 99 years - NCT06924697Enrolling by invitation
Testing a diabetes drug to help men quit smoking
This study tests if a medication used for type 2 diabetes (GLP-1 receptor agonists) can also reduce smoking in men with diabetes who smoke. If you qualify, you may receive this drug or a standard diabetes pill to see if it helps you smoke less.
Shanghai, Shanghai MunicipalityAges 18–75
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 792 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.